Peter K. Kaiser

39.6k total citations · 10 hit papers
465 papers, 27.4k citations indexed

About

Peter K. Kaiser is a scholar working on Ophthalmology, Radiology, Nuclear Medicine and Imaging and Mechanics of Materials. According to data from OpenAlex, Peter K. Kaiser has authored 465 papers receiving a total of 27.4k indexed citations (citations by other indexed papers that have themselves been cited), including 279 papers in Ophthalmology, 177 papers in Radiology, Nuclear Medicine and Imaging and 56 papers in Mechanics of Materials. Recurrent topics in Peter K. Kaiser's work include Retinal Diseases and Treatments (202 papers), Retinal Imaging and Analysis (107 papers) and Retinal and Optic Conditions (101 papers). Peter K. Kaiser is often cited by papers focused on Retinal Diseases and Treatments (202 papers), Retinal Imaging and Analysis (107 papers) and Retinal and Optic Conditions (101 papers). Peter K. Kaiser collaborates with scholars based in United States, Canada and Germany. Peter K. Kaiser's co-authors include Jeffrey S. Heier, David M. Brown, Robert Y. Kim, David S. Boyer, Philip J. Rosenfeld, Carol Chung, Mark Michels, Judy P. Sy, Ming Cai and G. Soubrane and has published in prestigious journals such as Science, New England Journal of Medicine and Neuron.

In The Last Decade

Peter K. Kaiser

442 papers receiving 25.9k citations

Hit Papers

Ranibizumab for Neovascular Age-Related Macular Degeneration 1999 2026 2008 2017 2006 2006 2012 2008 2013 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ranibizumab for Neovascular Age-Related Macular Degeneration
    2006 4.6k citations Philip J. Rosenfeld, Peter K. Kaiser et al. profile →
  2. Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
    2006 2.8k citations Peter K. Kaiser et al. profile →
  3. Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
    2012 1.8k citations Jean‐François Korobelnik, Peter K. Kaiser et al. Ophthalmology profile →
  4. Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study
    2008 1.1k citations Peter K. Kaiser et al. Ophthalmology profile →
  5. The International Vitreomacular Traction Study Group Classification of Vitreomacular Adhesion, Traction, and Macular Hole
    2013 793 citations Peter K. Kaiser et al. Ophthalmology profile →
  6. Estimation of rock mass deformation modulus and strength of jointed hard rock masses using the GSI system
    2003 496 citations Peter K. Kaiser et al. profile →
  7. Modelling brittle failure of rock
    2002 493 citations Peter K. Kaiser et al. profile →
  8. Design of rock support system under rockburst condition
    2012 462 citations Peter K. Kaiser et al. profile →
  9. Hoek-Brown parameters for predicting the depth of brittle failure around tunnels
    1999 404 citations Peter K. Kaiser et al. profile →
  10. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion–Related Events with Brolucizumab
    2020 238 citations Peter K. Kaiser, Frank G. Holz et al. Ophthalmology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter K. Kaiser United States 68 18.9k 14.3k 3.9k 3.1k 1.5k 465 27.4k
Milan Sonka United States 63 4.9k 0.3× 11.2k 0.8× 1.1k 0.3× 163 0.1× 91 0.1× 418 23.4k
Joachim Hornegger Germany 55 3.6k 0.2× 7.5k 0.5× 350 0.1× 105 0.0× 126 0.1× 448 13.5k
Haoyu Chen China 41 2.3k 0.1× 1.8k 0.1× 1.9k 0.5× 240 0.1× 117 0.1× 369 7.1k
Ken Hayashi Japan 47 5.1k 0.3× 4.2k 0.3× 470 0.1× 214 0.1× 73 0.0× 412 8.4k
Xinjian Chen China 47 1.4k 0.1× 3.0k 0.2× 1.0k 0.3× 238 0.1× 142 0.1× 405 8.6k
Gerhard A. Holzapfel Austria 79 252 0.0× 1.7k 0.1× 658 0.2× 4.1k 1.3× 940 0.6× 406 26.8k
Richard Skalak United States 52 209 0.0× 1.3k 0.1× 1.9k 0.5× 1.2k 0.4× 422 0.3× 186 18.5k
J. Stuart Nelson United States 76 1.7k 0.1× 6.5k 0.5× 1.1k 0.3× 998 0.3× 49 0.0× 605 23.4k
Stephen C. Cowin United States 62 62 0.0× 890 0.1× 2.2k 0.6× 6.1k 2.0× 1.3k 0.8× 214 19.3k
Ruikang K. Wang United States 75 9.3k 0.5× 11.1k 0.8× 2.1k 0.5× 535 0.2× 92 0.1× 939 23.5k

Countries citing papers authored by Peter K. Kaiser

Since Specialization
Citations

This map shows the geographic impact of Peter K. Kaiser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter K. Kaiser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter K. Kaiser more than expected).

Fields of papers citing papers by Peter K. Kaiser

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter K. Kaiser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter K. Kaiser. The network helps show where Peter K. Kaiser may publish in the future.

Co-authorship network of co-authors of Peter K. Kaiser

This figure shows the co-authorship network connecting the top 25 collaborators of Peter K. Kaiser. A scholar is included among the top collaborators of Peter K. Kaiser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter K. Kaiser. Peter K. Kaiser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kaiser, Peter K., Ananth Sastry, Amy Babiuch, et al.. (2025). Initial Functional and Anatomical Outcomes of High-dose Aflibercept 8 mg in Exudative Neovascular Age-related Macular Degeneration. Ophthalmology Retina. 9(8). 756–766. 5 indexed citations
2.
Shen, Liangbo L., Peter K. Kaiser, Jeremy Liu, et al.. (2025). Determinants of Four-Year Visual Acuity Loss in Geographic Atrophy. Ophthalmology. 132(7). 785–798. 2 indexed citations
3.
4.
5.
Xie, Jim Shenchu, Mark Phillips, Dena Zeraatkar, et al.. (2024). Exploring the fragility of meta-analyses in ophthalmology: a systematic review. Eye. 38(16). 3153–3160.
6.
Anegondi, Neha, Srinivas R. Sadda, Steffen Schmitz-Valckenberg, et al.. (2024). Visual Loss in Geographic Atrophy. Ophthalmology. 132(4). 420–430. 3 indexed citations
7.
Khanani, Arshad M., Peter K. Kaiser, Margaret Chang, et al.. (2024). Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy. Ophthalmology Retina. 8(11). 1052–1060. 9 indexed citations
8.
Schwabl, Christoph, Gernot Schmidle, Peter K. Kaiser, et al.. (2023). Nerve entrapment syndromes: detection by ultrasound. ULTRASONOGRAPHY. 42(3). 376–387. 13 indexed citations
9.
Xie, Jim Shenchu, Nikhil S. Patil, Mark Phillips, et al.. (2023). Anti‐vascular endothelial growth factor therapy and retinal non‐perfusion in diabetic retinopathy: A meta‐analysis of randomised trials. Acta Ophthalmologica. 102(1). e31–e41. 2 indexed citations
10.
Kaiser, Peter K., Paul Karpecki, Carl D. Regillo, et al.. (2023). Geographic Atrophy Management Consensus (GA-MAC): a Delphi panel study on identification, diagnosis and treatment. BMJ Open Ophthalmology. 8(1). e001395–e001395. 6 indexed citations
11.
Szigiato, Andrei-Alexandru, Katherine E. Talcott, Danny A. Mammo, et al.. (2023). Short-Term Outcomes of Faricimab in Patients with Neovascular Age-Related Macular Degeneration on Prior Anti-VEGF Therapy. Ophthalmology Retina. 8(1). 10–17. 39 indexed citations
12.
Khanani, Arshad M., Mathew Thomas, Aamir Aziz, et al.. (2022). Review of gene therapies for age-related macular degeneration. Eye. 36(2). 303–311. 80 indexed citations
13.
14.
Kastenberger, Tobias, et al.. (2020). Die Behandlung der avaskulären Kahnbeinpseudarthrose: gefäßgestielter Knochenspan vom Beckenkamm oder vom medialen Femurkondyl?. Handchirurgie · Mikrochirurgie · Plastische Chirurgie. 52(5). 419–424. 1 indexed citations
15.
Wang, Yimin, Mengxi Shen, Jin-Wei Cheng, Xiaodong Sun, & Peter K. Kaiser. (2020). The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review. Journal of Ophthalmology. 2020. 1–10. 2 indexed citations
16.
Kaiser, Peter K., Laurent Kodjikian, Jean‐François Korobelnik, et al.. (2019). Systemic pharmacokinetic/pharmacodynamic analysis of intravitreal aflibercept injection in patients with retinal diseases. BMJ Open Ophthalmology. 4(1). e000185–e000185. 13 indexed citations
17.
Uchida, Atsuro, Rishi P. Singh, Aleksandra Rachitskaya, et al.. (2018). Optical Coherence Tomography Angiography in Eyes with Indeterminate Choroidal Neovascularization. Ophthalmology Retina. 2(11). 1107–1117. 1 indexed citations
18.
Bewick, R. P. & Peter K. Kaiser. (2013). Discussion on “An Empirical Failure Criterion for Intact Rocks” by Peng et al. (2013). Rock Mechanics and Rock Engineering. 47(2). 817–823. 7 indexed citations
19.
Moshfeghi, Andrew A., Virgilio Morales-Cantón, Hugo Quiroz–Mercado, et al.. (2012). 16 Gy low-voltage x-ray irradiation followed by as needed ranibizumab therapy for age-related macular degeneration: 12 month outcomes of a ‘radiation-first’ strategy. British Journal of Ophthalmology. 96(10). 1320–1324. 10 indexed citations
20.
Kaiser, Peter K.. (2004). Verteporfin In Occult (VIO): The Design of a Phase III Controlled Clinical Trial of Verteporfin Therapy for Occult with No Classic Subfoveal CNV Secondary to AMD. Investigative Ophthalmology & Visual Science. 45(13). 2276–2276. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Milan Sonka Breakdown of academic impact, for papers by Joachim Hornegger Breakdown of academic impact, for papers by Haoyu Chen Breakdown of academic impact, for papers by Ken Hayashi Breakdown of academic impact, for papers by Xinjian Chen Breakdown of academic impact, for papers by Gerhard A. Holzapfel Breakdown of academic impact, for papers by Richard Skalak Breakdown of academic impact, for papers by J. Stuart Nelson Breakdown of academic impact, for papers by Stephen C. Cowin Breakdown of academic impact, for papers by Ruikang K. Wang
Rankless by CCL
2026